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Abutilon indicum (L.) Sweet is an Asian phytomedicine traditionally used to treat several disorders, including diabetes mellitus.
However, molecular mechanisms supporting the antidiabetic eﬀect of A. indicum L. remain unknown. The aim of this study
was to evaluate whether extract of A. indicum L. improves insulin sensitivity. First, we observed the antidiabetic activity of aqueous
extractoftheentireplant(leaves,twigsandroots)ofA.indicumL.onpostprandialplasmaglucoseindiabeticrats.Thesubsequent
experiments revealed that butanol fractions of the extract bind to PPARγ and activate 3T3-L1 diﬀerentiation. To measure glucose
uptake enhanced by insulin-like activity, we used rat diaphragm incubated with various concentrations of the crude extract and
found that the extract enhances glucose consumption in the incubated solution. Our data also indicate that the crude extract
and the fractions (water and butanol) did not aﬀect the activity of kinases involved in Akt and GSK-3β pathways; however, the
reporter assay showed that the crude extract could activate glucose transporter 1 (GLUT1) promoter activity. These results suggest
that the extract from A. indicum L. may be beneﬁcial for reducing insulin resistance through its potency in regulating adipocyte
diﬀerentiation through PPARγ agonist activity, and increasing glucose utilization via GLUT1.
1.Introduction
Diabetes mellitus (DM) is a group of metabolic diseases
characterized by hyperglycemia resulting from defects in
insulin secretion, insulin action, or both; the incidence of
diabetes is increasing worldwide. Diabetes or obesity causes
substantial morbidity, mortality and long-term complica-
tions, and remains an important risk factor for cardiovas-
cular disease [1]. There exists a genetic predisposition to
diabetes; however, environmental factors such as a sedentary
lifestyle and obesity are the most prominent risk factors [2].
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obesity and plays an important pathophysiological role [3].
Insulin resistance is characterized by a diminished reaction
of insulin-sensitive tissues and a marked decrease in glucose
metabolism in response to insulin. In fact, impairment of
insulinactionhasalsobeenobservedinsyndromesincluding
inﬂammatory and chronic infectious diseases in addition to
type 2 DM [4]. Recent data suggest that activation of PPARγ
by using plant extracts improves lipid metabolism and
mitigatesinsulinresistance[5].Throughouttheworld,many
traditional plant treatments for diabetes are employed that
are frequently considered to be less toxic and have fewer side
eﬀects than synthetic drug treatments [1, 6]. According to a
medicinal survey report in Thailand, traditional medicines
or herbs are used 31% of the time in the treatment of
diabeticpatients[7].However,traditionalantidiabeticplants
possess less adequate scientiﬁc or medicinal data support
in spite of the fact that the World Health Organization still
recommends further evaluation of their accepted use [8, 9].
The native Southeast Asian plant A. indicum (L.) Sweet is
an erect, branched shrub of 0.5–1m height, having the Thai2 Evidence-Based Complementary and Alternative Medicine
name Krob-Fun-Si, Fun-Si or Ma-Kong-Khaao. A. indicum
L. is in the family Malvaceae, is easily identiﬁed by its cog-
like fruits, and is found abundantly in wastelands. This
plant has a long history of being used medicinally as an
antidiabetic remedy, and phytochemical screening of the
plantrevealedthatitcontainedalkaloids,ﬂavonoids,tannins,
saponins and glycosides [10, 11]. This medicinal plant plays
an important role in folk medicine; in Thailand, it has
been used as a blood tonic, carminative, antipyretic, anti-
cough, diuretic, anti-inﬂammatory, laxative and antidiabetic
[12], whereas in India and China, it has been used for
urinary disease, gonorrhea, jaundice, rheumatism, high
fever, mumps, pulmonary tuberculosis, bronchitis, lack of
urination and some nervous and ear problems [13, 14].
According to many scientiﬁc reports, the leaf extracts possess
hypoglycemic, hepatoprotective, antibacterial and larvicidal
properties [10, 13, 15, 16]. Analgesic principles from this
plant were also isolated [17], and its polyherbal formulations
have been reported as being eﬀective in treating diabetes and
hyperlipidemia, and eﬀective as free radical scavengers [18–
20].
With respect to its traditional use, A. indicum L. has been
known to contain an active ingredient against diabetes and
is believed to reduce some symptoms of diabetic compli-
cations. In this study, we investigated whether the extracts
of A. indicum L. could reduce postprandial plasma glucose
levels in an animal model of diabetes, since postprandial
hyperglycemia is one of the common complications seen
in diabetic patients [21]. We found that A. indicum L.
ameliorates insulin resistance via PPARγ activation and
enhances glucose uptake.
2. Methods
2.1. Plant Material. The leaves, twigs and roots of A. indicum
(L.) Sweet were collected from Mahidol University, Salaya
Campus, Nakorn Pathom Province, Thailand, during May
2004, and were authenticated by Rungravi Temsiririrkkul,
Department of Pharmaceutical Botany, Faculty of Pharmacy,
Mahidol University. A voucher specimen (PBM 04765) was
deposited at the Pharmaceutical Botany Mahidol University
herbarium. All fresh parts were dried at 50◦C in a hot
air oven and then pulverized by an electric blender. Crude
extract was obtained by boiling 1kg of plant powder (leaves
261.2g, twigs 559.7g and root 179.1g) in 10l of distilled
water for 10min. The boiling process was repeated twice,
and the combined extract was ﬁltered across cotton wool
and gauze. The ﬁltrate was lyophilized in a freeze dry
system resulting in a dark brown powder of 11.44% w/w.
Lyophilized extract was preserved in an airtight bottle at
room temperature and protected from light until use. The
crude extract (10g) was subsequently partitioned between
butan-1-ol (3 × 0.2l) and distilled water (0.2l). The butanol
fraction was concentrated under reduced pressure in a rotary
evaporator and lyophilized to give a total semi-solid residue
(19% of dried crude extract). The resulting water fraction
was freeze-dried, followed by generating brown powder
(65.4% of dried crude extract).
2.2. Animals. Male Wistar rats, weighing 140–180g, were
purchased from the National Laboratory Animal Center,
Mahidol University, Salaya, Nakorn Pathom Province, Thai-
land. They were housed in a temperature-controlled room
(22–25◦C) with a 12h light-dark cycle for at least 1 week to
acclimatization. The animals were fed with free access to a
commercial pellet diet (C.P. Thailand) and water ad libitum.
The animal protocol was approved by the Animal Ethics
Committee, Faculty of Pharmacy, Mahidol University (No.
5/2548).
2.3. Preparation of Diabetic Rats. Diabetes was induced in
the 16 h-fasted male Wistar rats with a single intraperi-
toneal injection of 75mgkg−1 streptozotocin (STZ), freshly
dissolved in isotonic saline. Five days after injection, diabetic
rats were identiﬁed by measuring fasting plasma glucose
(FPG) levels using PGO enzyme (Sigma). Rats with FPG
levels over 200mgdl−1 were used in the experiment [22, 23].
2.4. Antidiabetic Activity of A. indicum Extract on Postpran-
dial Plasma Glucose. The STZ-induced diabetic rats were
randomly allocated into four groups (6–9 rats per group)
A. indicum crude extract and glibenclamide were dissolved
in distilled water and administered orally once a day for 2
weeks as follows: Group 1: diabetic rats treated orally with
distilled water (control), Group 2: diabetic rats treated orally
withglibenclamide5mgkg−1 bodyweight(positivecontrol),
Groups 3 and 4: diabetic rats treated orally with crude
extract 0.25 or 0.5gkg−1 body weight. Blood samples (60μl
of each) were collected from the tail vein using Hematocrit-
capillary tube, after 2h fasting on day 0 (1 day before
oral administration), day 7 and day 14 for plasma glucose
determination. The animals were weighed on day 0, 4, 7, 11
and 14 for corrected doses of medication.
2.5. Cell Cultures. HCT-116, HepG2, C2C12, 3T3-L1 and L6
cellswerepurchasedfromAmericanTypeCultureCollection
(Manassas, VA, USA). HCT-116 cells were maintained in
McCoy’s 5A medium supplemented with 10% FBS; all
others were maintained in DMEM supplemented with 10%
FBS. Cells were grown at 37◦C in a humidiﬁed, 5% CO2
environment. For adipocyte diﬀerentiation, diﬀerentiation
medium containing 0.5mM isobutyl methylxanthine, 1μM
dexamethasone and 1μgml −1 insulin was added to the
culture. The diﬀerentiation media was changed every 2 days
until day 4. Thereafter, DMEM containing 10% FBS and
insulin was subsequently replaced every 2 days until day 8.
C2C12 and L6 myoblasts were diﬀerentiated with DMEM
containing 2% horse serum for 6 and 2 days, respectively.
2.6. Binding Activity of A. indicum Extract to PPARα and
PPARγ. HCT-116 cells were plated in 12-well plates at a
concentration of 2 × 105 cells/well. After growth for 18h,
transient transfections were performed using lipofectamine
(Invitrogen, Carlsbad, CA, USA) according to the manufac-
turer’s instructions. MH 100×4-TK-LUC plasmid, pCMX-
Gal-mPPARα-LBD, and pCMX-Gal-mPPARγ-LBD (0.25μg
each)wereco-transfectedwithpRL-nullvector(0.05μg)intoEvidence-Based Complementary and Alternative Medicine 3
the cells. The transfected cells were cultured in the absence
or presence of various concentrations of crude extract, water
or butanol fraction for 24h. Cells were harvested in 1×
luciferase lysis buﬀer, and luciferase activity was normalized
tothepRLnullluciferaseactivityusingadualluciferaseassay
kit (Promega, Madison, WI, USA). Assays were performed in
triplicate for each experiment group as previously described
[24].
2.7. Analysis of mRNA Expression during Adipocyte Diﬀer-
entiation. Total RNA was extracted from 3T3-L1 cells at
day 0 (before diﬀerentiation), 2, 4, 6 and 8 after differen-
tiation using the PerfectPure RNA puriﬁcation kit accord-
ing to the manufacturer’s instructions (5Prime, Gaithers-
burg, MD, USA). Reverse transcription (RT) was per-
formed on 1μg of RNA samples using an iScript cDNA
synthesis kit in a ﬁnal volume of 20μl, according to
the manufacturer’s instructions (Bio Rad, Hercules, CA,
USA). Speciﬁc oligonucleotide primers were designed
using the Primer3 program (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3 www.cgi). Quantitative changes in
mRNAexpressionwereassessedwithasemi-quantitativeRT-
PCR, using speciﬁc primers (Table 1). The PCR products
were separated electrophoretically in a 2% agarose gel and
stained with ethidium bromide.
2.8. Glucose Consumption Assay. Adult male Wistar rats
weighing 180–200g were used in this experiment. Ani-
mals were fasted for 36h and sacriﬁced by inhalation of
diethyl ether. The thorax was opened, and the diaphragm
was removed. The diaphragm was immediately placed
in oxygenated nutrient solution (125ml of aerated 1.3%
NaHCO3 was added to 750ml of 0.16M NaCl, 5.4mM KCl,
2.7mM CaCl2, 4.2mM NaHCO3,1 . 4 m MM g S O 4·7H2O,
and 1.5mM KH2PO4). The diaphragm was cleaned of fat
and connective tissue and cut into 6 pieces before being
suspended in a nutrient solution organ bath containing
300mgdl−1 of glucose and bubbled with carbogen at 37◦C
[25]. Then, the crude extracts or insulin (used as the positive
control) was added as follows: Group 1: incubated in only
nutrient solution (control group), Group 2: crude extract
at a concentration of 0.04mgdl−1, Group 3: crude extract
at a concentration of 0.2mgdl−1, Group 4: crude extract
at a concentration of 1.0mgdl−1, Group 5: crude extract
at a concentration of 5.0mgdl−1, and Group 6: insulin
1 unitml−1 (positive control). After 90min of incubation,
the concentration of remaining glucose in the solution was
measured, and each piece of diaphragm was dried. The
results were expressed as glucose consumption per 10mg dry
diaphragm.
2.9. GLUT1 Luciferase Reporter Assay. L6 myocytes in 48-
well plates were co-transfected using FuGENE6 (Roche,
Indianapolis, IN, USA) with 0.25μgG L U T 1p r o m o t e r
(generously provided by Dr Birnbaum at the University of
Pennsylvania, Philadelphia, PA, USA) and 0.025μgo fp R L -
SV40 plasmid. After 30h of transfection, cells were exposed
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Figure 1: The eﬀect of crude extract of A. indicum on 2h
postprandial plasma glucose in STZ-induced diabetic rats. The
results show the mean ± SEM, (n = 6–9). Asterisks represents
statistical signiﬁcance (P < .05) compared with control at each
day. Double asterisk represent statistical signiﬁcance (P < .05) both
compared with control at each day and day 0 within the group.
to various concentrations of crude extract in HEPES-
buﬀered saline, pH 7.4, containing 2% horse serum with
5mM glucose for 16h. The cells were washed twice with PBS
and then assayed for luciferase activity as shown above.
2.10. Statistical Analysis. The data were presented as the
mean ± standard error of the mean (SEM). Statistical
analysis was performed using the Student’s t-test or analysis
of variance (ANOVA) followed by the least signiﬁcant
diﬀerences (LSD) test. The signiﬁcance of diﬀerences was set
at P-value < .05.
3. Results
3.1. Postprandial Plasma Glucose in STZ-Induced Diabetic
Rats. As shown in Figure 1, administration of A. indicum
crude extract signiﬁcantly lowered (P < .05) 2h postpran-
dial plasma glucose concentrations of treated groups in
comparison to those of control STZ-diabetic rats at the
corresponding time. A similar signiﬁcant decrease was also
observed in rats treated with glibenclamide. However, prior
to treatment administration (day 0), basal plasma glucose
concentration did not signiﬁcantly diﬀer between groups.
3.2. Binding Activity to Peroxisome Proliferator-Activated
Receptors. To examine whether A. indicum extracts activate
peroxisome proliferator-activated receptor (PPAR) respon-
siveness,HCT-116cellsweretransfectedwithfourcopiesofa
Gal4 binding site (MH100x4-TK-LUC) and chimeric recep-
tors (pCMX-Gal-mPPARα-LBD or pCMX-Gal-mPPARγ-
LBD). In this system, when a compound binds to the
ligand binding domain (LBD) of the PPARα or PPARγ
chimeric receptor, the DNA binding domain of the yeast
Gal4 binds to the co-transfected Gal4 binding site and
initiates transcription of the ﬁreﬂy luciferase (LUC). After4 Evidence-Based Complementary and Alternative Medicine
Table 1: Primer sequences used for RT-PCR.
Gene Sense Sequence
Adiponectin Forward 5 -TGC ACA GCT CCG TGT ACT TC-3 
Reverse 5 -CAC CTG CAC AGA GTC GTC AT-3 
aP2 Forward 5 -AAG AAG TGG GAG TGG GCT TT-3 
Reverse 5 -CTT GTG GAA GTC ACG CCT TT-3 
LPL Forward 5 -GGA TCC GTG GCC GCA GCA GAC GCA GGA AGA-3 
Reverse 5 -GAA TTC CAT CCA GTT GAT GAA TCT GGC CAC-3 
PPARγ Forward 5 -GGT GAA ACT CTG GGA GAT TC-3 
Reverse 5 -CAA CCA TTG GGT CAG CTC TT-3 
GAPDH Forward 5 -CAG GAG CGA GAC CCC ACT AAC AT-3 
Reverse 5 -GTC AGA TCC ACG ACG GAC ACA TT-3 
c e l l sw e r et r e a t e dw i t hc r u d ee x t r a c tf o r2 4 h ,l u c i f e r a s e
activitiesweremeasuredtoassessthetransactivationforeach
PPAR receptor. As shown in Figures 2(a) and 3(a),c r u d e
extract 100μgml −1 showed 1.6- and 1.4-fold increases of
transactivationtoPPARαandPPARγ,respectively,indicating
that crude extract contains compounds that bind to PPARα
and PPARγ.
The activation of PPARα and PPARγ using water and
butanol fractions was also investigated. The results revealed
that the water fraction has a minimal eﬀect on PPARα
and PPARγ activation, whereas butanol fractions showed a
dose-dependent increase of PPARα and PPARγ activation
(Figures 2(b) and 3(b)). The concentration of butanol
fraction (100μgml −1) showed 5.5- and 3.2-fold increases
of transactivation to PPARα and PPARγ, respectively. These
results suggest that the butanol fraction, but not the water
fraction, contains a substance that activates PPARα and
PPARγ.
3.3. mRNA Expression during Preadipocyte Diﬀerentiation.
Since butanol fraction binds to PPARγ and transactivates
PPARγ a c t i v i t y ,g e n ee x p r e s s i o np r o ﬁ l e sw e r eo b s e r v e dt o
elucidate whether the butanol fraction actually induces
adipocytediﬀerentiationthroughPPARγ activation.Twenty-
four hours before and during diﬀerentiation, butanol frac-
tionat100μgml −1 wasaddedtothemediumforobservation
of its eﬀects on gene expression during 3T3-L1 adipocyte
diﬀerentiation. Dimethyl sulfoxide (DMSO) was used as
vehicle control. As shown in Figure 4, cells treated with the
butanol fraction increased the expression of PPARγ, aP2,
and adiponectin at day 8, consistent with the previous data
indicating that butanol fraction enhances PPARγ activity
(Figure 3(b)). However, there was no change in mRNA level
of lipoprotein lipase (LPL) throughout the diﬀerentiation.
3.4. Glucose Consumption. Crude extract of A. indicum was
tested for insulin-like eﬀect using diaphragm of rat. Pieces of
diaphragms were incubated with various concentrations of
the crude extract for 1.5h. As shown in Figure 5, the extract
enhanced glucose uptake in a concentration-dependent
manner. The extract between concentrations of 1–5mgml−1
signiﬁcantly increased glucose uptake and showed an almost
maximal eﬀect on glucose uptake at the concentration of
1mgml −1. Insulin was used as a positive control and also
showed an ∼1.7-fold induction over the untreated group.
3.5. Protein Expression in Insulin Signaling Pathway and
GLUT1 Promoter Activation. Since protein kinases B (Akt)
and glycogen synthase kinase 3β (GSK3β) are major kinases
of the insulin signaling pathway [26, 27], the eﬀects of
crude extract and butanol and water fractions on phospho-
rylation of Akt and GSK3β in C2C12 myotubes and 3T3-
L1 adipocytes were examined. However, no changes were
detected in Akt phosphorylation or GSK3β phosphorylation,
although insulin activated these two biochemical markers
(data not shown), suggesting that extracts and fractions do
not aﬀect the Akt/GSK3β pathway. To determine the eﬀect
of crude extract on the transcriptional activity of Glut1,a
pGL3-GLUT1 luciferase construct that contains –2100bp
of the rat Glut1 promoter region was transfected into L6
cells. After transfection, the cells were treated with various
concentrations of crude extract for 16h, and luciferase
activity was measured. As shown in Figure 6, the cells treated
with the extract increased relative luciferase unit (RLU) in
a dose-response manner. A signiﬁcant fold increase against
untreated cells was found in the cells treated with 100 and
500μgml −1 of crude extract.
4. Discussion
Much research eﬀort is currently directed toward develop-
ment of adipogenesis and lipogenesis studies, and a number
of antidiabetic compounds have been developed and tested
for their eﬀects. For example, thiazolidinediones (TZDs),
synthetic PPARγ ligands, are a novel class of antidiabetic
drugs for patients with type 2 diabetes, and two of these,
rosiglitazone and pioglitazone, are currently available for
clinical use [28]. Originally, TZDs were identiﬁed based
on their antihyperglycemic activity, but they are also able
to improve other abnormalities associated with type 2
diabetes, such as hyperlipidemia, atherosclerosis, hyperten-
sion, chronic inﬂammation and ﬁbrinolytic state. It is well
established that PPARγ agonists such as TZDs promote
the adipogenesis of 3T3-L1 cells, which have been used
for the development of antidiabetic compounds [29–31].
Since troglitazone (TGZ) was voluntarily withdrawn fromEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: (a) The eﬀect of A. indicum crude extract on luciferase
activity of PPARα. After the cells were transiently transfected
with four copies of a Gal4 binding site (MH100×4-TK-LUC)
and chimeric receptors pCMX-Gal-mPPARα-LBD, the cells were
treated with vehicle (DMSO, control), WY14643 (positive control)
or diﬀerent concentrations of crude extract for 24h and luciferase
activity was measured. The data are presented as relative luciferase
activity(ﬁreﬂyluciferase signal/renillaluciferasesignal).Theresults
show the mean ± SEM of three independent transfections. ∗P <
.01 versus vehicle-treated cells. (b) The eﬀect of water and butanol
fractions on luciferase activity of PPARα. The data are presented as
relative luciferase activity (ﬁreﬂy luciferase signal/renilla luciferase
signal). The results show the mean ± SEM of three independent
transfections. ∗P < .01 versus vehicle-treated cells.
the market in March 2000 due to occurrence of severe
idiosyncratic liver injury, it is necessary to establish a safer
compoundthatshowsantidiabeticactivity.Manyresearchers
have focused on the study of dietary phytochemicals found
in plants. In this report, we examined whether the extract
of A. indicum has antidiabetic activity in STZ-induced
diabetic rats. The results demonstrated that administra-
tion of A. indicum extract at 0.25 and 0.5gkg−1 resulted
in signiﬁcant decreases of postprandial plasma glucose,
as seen in glibenclamide-treated rats. Although gliben-
clamide lowers plasma glucose level, mainly by stimulating
insulin secretion from pancreatic β-cells [32], destruction of
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Figure 3: (a) The eﬀect of A. indicum crude extract on luciferase
activity of PPARγ. After the cells were transiently transfected
with four copies of a Gal4 binding site (MH100×4-TK-LUC) and
chimeric receptors pCMX-Gal-mPPARγ- L B D ,t h e yw e r et r e a t e d
with vehicle (DMSO, control), TGZ (positive control) or diﬀerent
concentrations of crude extract for 24h and luciferase activity was
measured. The data are presented as relative luciferase activity
(ﬁreﬂy luciferase signal/renilla luciferase signal). The results show
the mean ± SEM of three independent transfections. ∗P < .01
versus vehicle-treated cells. (b) The eﬀect of water and butanol
fractions on luciferase activity of PPARγ. The data are presented as
relative luciferase activity (ﬁreﬂy luciferase signal/renilla luciferase
signal). The results show the mean ± SEM of three independent
transfections. ∗P < .01 versus vehicle-treated cells.
β-cells are observed in STZ-induced diabetes model (type 1
diabetes) [33]. Thus, extrapancreatic action such as stimu-
lating liver and muscle fructose-2,6-bisphosphate formation
may be involved in the eﬀect of both glibenclamide and
extracts used in this study rather than insulin secretion.
In fact, it has been known that the extrapancreatic action
of glibenclamide has an important role to inhibit glucose
production by liver and improve carbohydrate metabolism
in diabetes [34, 35], and increases glucose disposal by
stabilizing GLUT1 protein at the plasma membrane of
muscle [36]. Subsequently, we found that crude extract of A.
indicum acts as a PPARγ ligand. Further, the data indicated6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: The eﬀect of butanol fraction of A. indicum to induce
mRNA expression of the PPARγ target gene. 3T3-L1 preadipocyte
cells were diﬀerentiated. Twenty-four hours before and during
diﬀerentiation, cells were treated with vehicle control (DMSO) or
100μgml −1 of butanol fraction. mRNA expression of PPARγ,L P L ,
aP2, adiponectin and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) were measured at Days 0, 2, 4, 6 and 8 of diﬀerentiation.
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Figure 5: Eﬀect of A. indicum crude extract on muscle glucose
consumption. Diaphragms were isolated from fasted Wistar rats
and incubated with 300mgdl−1 of glucose in the absence or
presence of crude extract for 90min. The glucose consumption was
expressed as disappeared glucose into diaphragm per 10mg dry
diaphragm. Data are presented as means ± SEM of eight replicates.
Statistical analysis was performed using ANOVA followed by LSD.
∗P < .05 compared with the untreated group.
that the butanol fraction (non-polar part) may contain a
compound that induces PPARγ activity (Figure 3(b)). The
present study also demonstrates that the butanol fraction
enhances 3T3-L1 adipocyte diﬀerentiation by an increase of
accumulation of diﬀerentiation and fat cell marker genes
(Figure 4). The accumulation of these mRNA reﬂects both
the rate of initiation of transcription and the half time of
degradation of those transcripts.
At the molecular level, adipogenesis is driven by a
complex transcriptional cascade involving the sequential
activation of CCAAT/enhancer binding proteins (C/EBPs)
and PPARγ [37]. Loss-of-function studies have convincingly
shown that PPARγ is necessary as well as suﬃcient to
promote adipogenesis and that C/EBPα is inﬂuential by
maintaining the expression of PPARγ and promoting full
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Figure6:TheeﬀectofA.indicumcrudeextractonthetranscription
level of Glut1.L 6m y o c y t e sw e r et r a n s f e c t e dw i t hG L U T 1p r o m o t e r
and pRL-SV40 plasmid. Then, cells were exposed to indicate
concentrations of crude extract for 16h as described in the
‘Methods’ section. The luciferase activity was expressed as a ratio
of ﬁreﬂy to renilla luciferase activity. Transfections and assays were
performed in triplicate for each experiment group. Data showed
mean ± SEM of fold increase of three replicates against control
group. ∗P <.05compared withuntreatedsamplegroup.ThepGL3-
B a s i cv e c t o r( e m p t y )w a su s e da san e g a t i v ec o n t r o l ,a n dp G L 3 -
control vector was used for a positive control.
insulin sensitivity [38]. Our data indicate that exposing 3T3-
L1preadipocytes to thebutanolfractionduring adipogenesis
increases PPARγ mRNA, as well as the adipocyte-speciﬁc
fatty acid binding protein (aP2) mRNA level; aP2 is one
of the genes that characterizes the adipocyte phenotype
[37, 39]. Interestingly, the mRNA level of adiponectin in the
butanol fraction-treated group was higher than the control
throughout the diﬀerentiation. Adiponectin is exclusively
expressed by mature adipocytes and is the most abundant
circulating adipokine. Thus, these data imply that the
butanol fraction of A. indicum extract enhances adipogenesis
throughPPARγ activation.Hypoadiponectinemia appearsto
play an important causal role in insulin resistance, type 2
DM and metabolic syndrome [40, 41]. We could not exclude
thepossibility that butanolfractionaﬀectsmRNA stability of
those genes, and further studies may require elucidating the
molecular mechanism by which butanol fraction aﬀects gene
induction during adipogenesis. Since LPL (a PPARγ target
gene) did not increase in the presence of butanol fraction, it
is possible that butanol fraction may aﬀect gene induction
in a PPARγ-independent manner. The data also showed that
butanol fraction increased the activity of PPARα;h o w e v e r ,
further work to investigate expression of the PPARα target
gene is required to claim that the extract of A. indicum
acts as a PPARα/γ dual agonist. Indeed, PPARα agonists,
such as ﬁbrates, have been used to treat hypertriglyceridemia
and reduce cardiovascular risk [42]. Dual PPARα/γ agonists
hold promise to be able to combine the properties of TZDs
and ﬁbrates, as well as improve the management of type
2 diabetes and provide an eﬀective therapeutic option for
treating the multifactorial components of cardiovascular
disease, metabolic syndrome [43], and even cancer.Evidence-Based Complementary and Alternative Medicine 7
Filtrate from boiling with distilled water
Crude extract ↓Postprandial plasma glucose
1. TZD-Iike activity
↑PPARγ ligand binding activity
(PPARγ agonist)
Partition crude extract
with H2O:C 4H10O
Water fraction Butanol fraction
No eﬀect ↑↑TZD-like activity
↑Adipocyte diﬀerentiation
-↑aP2
-↑PPARγ
-↑Adiponectin
2.Insulin-like activity
↑Peripheral glucose utilization
2.1. No eﬀects on insulin signaling
A.indicum
(leaves, twigs, roots)
(In vivo)
pathway (pAkt, pGSK3β)
2.2. ↑Promoter activity of GLUT1
Figure 7: Summary of antidiabetic eﬀects against insulin resistance of A. indicum Sweet.
Another important ﬁnding of this work is that the
extract of A. indicum possessed considerable insulin-like
properties, as evidenced by enhancement of glucose uptake
in the diaphragm, which represents muscle cells that are the
major site of insulin-stimulated glucose disposal [44]. In
the follow-up studies, we examined potential mechanisms
underlying the improvement in glucose utilization by the
extract. The defective glucose transport system may play
an important role in the pathogenesis of peripheral insulin
resistance, and glucose uptake in target tissues is a critical
step in maintaining glucose homeostasis and in clearing
the postprandial glucose load [45]. Thus, we examined the
possibility that the extract may stimulate glucose transport
through a mechanism similar to insulin signaling in C2C12
myotubes and 3T3-L1 adipocytes. Previous literature has
documented that the phosphatidylinositol-3-kinase (PI3K)
pathway plays an important role in the insulin signaling
cascade leading to glucose transport translocation [44].
However, the results showed that under basal or insulin-
stimulated conditions, all of the extract treatments (crude
extract, water and butanol fraction) had no eﬀect on
Akt serine phosphorylation in either cell type (data not
shown).Anotherpathwaythathasbeenimplicatedinglucose
transport, not by translocation of GLUT, but by activation of
GLUT, is the p38 pathway [46], which is also interesting for
further study. This pathway has been reported to be involved
in the regulation of GLUT 1 expression [47]. Subsequently,
we examined the eﬀect of the extract on transcription
activation of GLUT1. As demonstrated in this study, extract
of A. indicum activated transcription of GLUT1 in a dose-
response manner, suggesting involvement of GLUT1 in
increasing glucose uptake by the extract. This result will
require conﬁrmation such as measuring extracellular signal
regulated kinases (ERKs), which have been known to be
responsible for the expression of GLUT1 [48].
We have reported that the phytochemical analysis of
the whole plant extract revealed the presence of alkaloids,
ﬂavonoids, and tannins [11]. Results from other researchers
have shown that this plant also contains saponins and
glycosides [10]. Most plants with antidiabetic properties
have been found to contain metabolites such as glycosides,
alkaloids and ﬂavonoids [9]. Indeed, seven compounds were
isolated from A. indicum extract and six of them identi-
ﬁed as β-sitosterol, oleanolic acid, (24R)-α-stigmastane-3,6-
dione, daucosterol, 2,6-dimethoxy-1,4-benzoquinone, and
vanillic acid [49]. Oleanolic acid has been reported to
have hypoglycemic activity by acting as an inhibitor of
glycogen phosphorylase, leading to the inhibition of hepatic
glycogenolysis [50]. The alkaloid berberine has also been
reported to activate GLUT1-mediated glucose uptake [48].
Thus, these results provide evidence that these compounds
may lead to aﬀect the antidiabetic activity of A. indicum.
The ﬁndings of antidiabetic properties in this study are
summarized in Figure 7, and support the ethnobotanical use
of A. indicum in the context of human type 2 DM; however,
the molecules of action responsible for A. indicum’s eﬀect
remain to be identiﬁed.
Funding
The Center of Excellence in Livestock Diseases and Human
Health at the University of Tennessee and a National
InstitutesofHealthgrant(R21CA109423).Financialsupport
was provided by the Royal Golden Jubilee PhD Program
(PHD/0245/2545) and the Oﬃce of the Higher Education
Commission, Thailand (to C.K.).8 Evidence-Based Complementary and Alternative Medicine
Acknowledgment
The authors thank Misty Bailey for her critical reading of
manuscript.
References
[ 1 ]G .Y .Y e h ,D .M .E i s e n b e r g ,T .J .K a p t c h u k ,a n dR .S .P h i l l i p s ,
“Systematic review of herbs and dietary supplements for
glycemic control in diabetes,” Diabetes Care,v o l .2 6 ,n o .4 ,p p .
1277–1294, 2003.
[2] S. Samane, J. No¨ el, Z. Charrouf, H. Amarouch, and P. S.
Haddad, “Insulin-sensitizing and anti-proliferative eﬀects of
Argania spinosa seedextracts,”Evidence-BasedComplementary
and Alternative Medicine, vol. 3, no. 3, pp. 317–327, 2006.
[3] P.Vollenweider,“Insulinresistantstatesandinsulinsignaling,”
Clinical Chemistry and Laboratory Medicine,v o l .4 1 ,n o .9 ,p p .
1107–1119, 2003.
[4] T.-P. Liu, C.-S. Lee, S.-S. Liou, I.-M. Liu, and J.-T. Cheng,
“Improvement of insulin resistance by Acanthopanax sen-
ticosus root in fructose-rich chow-fed rats,” Clinical and
Experimental Pharmacology and Physiology, vol. 32, no. 8, pp.
649–654, 2005.
[5] C.-C. Shih, C.-H. Lin, W.-L. Lin, and J.-B. Wu, “Momordica
charantia extract on insulin resistance and the skeletal muscle
GLUT4 protein in fructose-fed rats,” Journal of Ethnopharma-
cology, vol. 123, no. 1, pp. 82–90, 2009.
[6] P. S. Haddad, G. A. Azar, S. Groom, and M. Boivin, “Natural
healthproducts,modulationofimmunefunctionandpreven-
tion of chronic diseases,” Evidence-Based Complementary and
Alternative Medicine, vol. 2, no. 4, pp. 513–520, 2005.
[7] W. Aekplakorn, R. P. Stolk, B. Neal et al., “The prevalence and
management of diabetes in Thai adults: the International Col-
laborative Study of Cardiovascular Disease in Asia,” Diabetes
Care, vol. 26, no. 10, pp. 2758–2763, 2003.
[8] A. M. Gray, Y. H. A. Abdel-Wahab, and P. R. Flatt, “The
traditional plant treatment, Sambucus nigra (elder), exhibits
insulin-like and insulin-releasing actions in vitro,” Journal of
Nutrition, vol. 130, no. 1, pp. 15–20, 2000.
[9] A. A. Odetola, O. Akinloye, C. Egunjobi, W. A. Adekunle, and
A. O. Ayoola, “Possible antidiabetic and antihyperlipidaemic
eﬀectoffermentedParkiabiglobosa(JACQ)extractinalloxan-
induced diabetic rats,” Clinical and Experimental Pharmacol-
ogy and Physiology, vol. 33, no. 9, pp. 808–812, 2006.
[10] Y. N. Seetharam, G. Chalageri, S. R. Setty, and Bheemachar,
“Hypoglycemic activity of Abutilon indicum leaf extracts in
rats,” Fitoterapia, vol. 73, no. 2, pp. 156–159, 2002.
[11] C. Krisanapun, P. Peungvicha, R. Temsiririrkkul, and Y.
Wongkrajang, “Aqueous extract of Abutilon indicum Sweet
inhibits glucose absorption and stimulates insulin secretion in
rodents,” Nutrition Research, vol. 29, no. 8, pp. 579–587, 2009.
[12] W. Chuakul, P. Saralamp, W. Paonil, R. Temsiririrkkul, and T.
Clayton, Medical Plants in Thailand, vol. II, Amarin, Bangkok,
Thailand, 1997.
[13] A. Abdul Rahuman, G. Gopalakrishnan, P. Venkatesan, and
K. Geetha, “Isolation and identiﬁcation of mosquito larvicidal
compound from Abutilon indicum (Linn.) Sweet,” Parasitology
Research, vol. 102, no. 5, pp. 981–988, 2008.
[14] S. S. Deokule and M. W. Patale, “Pharmacognostic study of
Abutilon indicum,( L . )S w e e t , ”Journal of Phytological Research,
vol. 15, pp. 1–6, 2002.
[15] E. Porchezhian and S. H. Ansari, “Hepatoprotective activity
of Abutilon indicum on experimental liver damage in rats,”
Phytomedicine, vol. 12, no. 1-2, pp. 62–64, 2005.
[16] J. Parekh and S. Chanda, “Antibacterial and phytochemical
studies on twelve species of Indian medicinal plants,” African
Journal of Biomedical Research, vol. 10, pp. 175–181, 2007.
[17] M. Ahmed, S. Amin, M. Islam, M. Takahashi, E. Okuyama,
and C. F. Hossain, “Analgesic principle from Abutilon
indicum,” Pharmazie, vol. 55, no. 4, pp. 314–316, 2000.
[18] K. R. Kohli, G. Shilin, and S. A. Kolhapure, “Evaluation of
the clinical eﬃcacy and safety of Diabecon in NIDDM,” The
Antiseptic, vol. 101, pp. 487–494, 2004.
[19] S. K. Mitra, S. Gopumadhavan, T. S. Muralidhar, S. D.
Anturlikar, and M. B. Sujatha, “Eﬀect of a herbomineral
preparation D-400 in streptozotocin-induced diabetic rats,”
Journal of Ethnopharmacology, vol. 54, no. 1, pp. 41–46, 1996.
[20] A. R. Kishan, M. Ajitha, and K. Rajanarayana, “Antidiabetic,
antihyperlipidemic and free radical scavenging activities of an
Ayurvedicmedicine,”IndianDrugs,vol.37,no.3,pp.130–132,
2000.
[ 2 1 ]M .B h a t ,S .K .K o t h i w a l e ,A .R .T i r m a l e ,S .Y .B h a r g a v a ,a n d
B. N. Joshi, “Antidiabetic properties of Azardiracta indica
and Bougainvillea spectabilis: in vivo studies in murine dia-
betes model,” Evidence-Based Complementary and Alternative
Medicine. In press.
[22] P. Peungvicha, S. S. Thirawarapan, R. Temsiririrkkul, H.
Watanabe, J. Kumar Prasain, and S. Kadota, “Hypoglycemic
eﬀect of the water extract of Piper sarmentosum in rats,”
Journal of Ethnopharmacology, vol. 60, no. 1, pp. 27–32, 1998.
[23] A. O. Abdel-Zaher, S. Y. Salim, M. H. Assaf, and R. H. Abdel-
Hady, “Antidiabetic activity and toxicity of Zizyphus spina-
christileaves,”JournalofEthnopharmacology,vol.101,no.1–3,
pp. 129–138, 2005.
[24] S.-H. Lee, K. Yamaguchi, J.-S. Kim et al., “Conjugated linoleic
acid stimulates an anti-tumorigenic protein NAG-1 in an
isomer speciﬁc manner,” Carcinogenesis,v o l .2 7 ,n o .5 ,p p .
972–981, 2006.
[25] F. Sanchez de Medina, M. J. Gamez, I. Jimenez, J. Jimenez, J.
I. Osuna, and A. Zarzuelo, “Hypoglycemic activity of juniper
’berries’,” Planta Medica, vol. 60, no. 3, pp. 197–200, 1994.
[26] W. Shang, Y. Yang, L. Zhou, B. Jiang, H. Jin, and M. Chen,
“Ginsenoside Rb1 stimulates glucose uptake through insulin-
like signaling pathway in 3T3-L1 adipocytes,” Journal of
Endocrinology, vol. 198, no. 3, pp. 561–569, 2008.
[27] J. Lee and M.-S. Kim, “The role of GSK3 in glucose home-
ostasis and the development of insulin resistance,” Diabetes
ResearchandClinicalPractice,vol.77,no.3,pp.S49–S57,2007.
[28] H. Yki-J¨ arvinen, “Thiazolidinediones,” The New England
Journal of Medicine, vol. 351, no. 11, pp. 1106–1158, 2004.
[29] H. Zhang, H. Matsuda, S. Nakamura, and M. Yoshikawa,
“Eﬀects of amide constituents from pepper on adipogenesis
in 3T3-L1 cells,” Bioorganic and Medicinal Chemistry Letters,
vol. 18, no. 11, pp. 3272–3277, 2008.
[30] C.Kausch,J.Kr¨ utzfeldt,A.Witkeetal.,“Eﬀectsoftroglitazone
on cellular diﬀerentiation, insulin signaling, and glucose
metabolism in cultured human skeletal muscle cells,” Bio-
chemical and Biophysical Research Communications, vol. 280,
no. 3, pp. 664–674, 2001.
[31] F. Chiarelli and D. Di Marzio, “Peroxisome proliferator-
activated receptor-γ agonists and diabetes: current evidence
and future perspectives,” Vascular Health and Risk Manage-
ment, vol. 4, no. 2, pp. 297–304, 2008.Evidence-Based Complementary and Alternative Medicine 9
[32] A. J. Krentz and C. J. Bailey, “Oral antidiabetic agents: current
role in type 2 diabetes mellitus,” Drugs, vol. 65, no. 3, pp. 385–
411, 2005.
[33] T. Szkudelski, “The mechanism of alloxan and streptozotocin
action in B cells of the rat pancreas,” Physiological Research,
vol. 50, no. 6, pp. 537–546, 2001.
[ 3 4 ]K .H a t a o ,K .K a k u ,M .M a t s u d a ,M .T s u c h i y a ,a n dT .K a n e k o ,
“Sulfonylurea stimulates liver fructose-2,6-bisphosphate for-
mation in proportion to its hypoglycemic action,” Diabetes
Research and Clinical Practice, vol. 1, pp. 49–53, 1985.
[35] M. Matsuda, K. Kaku, and T. Kaneko, “Regulation of
muscle fructose 2, 6-bisphosphate levels by sulfonylureas,”
Endocrinologia Japonica, vol. 33, no. 6, pp. 913–917, 1986.
[36] E. Tsiani, T. Ramlal, L. A. Leiter, A. Klip, and I. G. Fan-
tus, “Stimulation of glucose uptake and increased plasma
membrane content of glucose transporters in L6 skeletal
muscle cells by the sulfonylureas gliclazide and glyburide,”
Endocrinology, vol. 136, no. 6, pp. 2505–2512, 1995.
[37] E. D. Rosen and B. M. Spiegelman, “Molecular regulation
of adipogenesis,” Annual Review of Cell and Developmental
Biology, vol. 16, pp. 145–171, 2000.
[38] S. R. Farmer, “Transcriptional control of adipocyte forma-
tion,” Cell Metabolism, vol. 4, no. 4, pp. 263–273, 2006.
[39] M. Hassan, C. E. Yazidi, J.-F. Landrier, D. Lairon, A. Margotat,
and M.-J. Amiot, “Phloretin enhances adipocyte diﬀerentia-
tion and adiponectin expression in 3T3-L1 cells,” Biochemical
and Biophysical Research Communications, vol. 361, no. 1, pp.
208–213, 2007.
[40] T. Kadowaki, T. Yamauchi, N. Kubota, K. Hara, K. Ueki, and
K. Tobe, “Adiponectin and adiponectin receptors in insulin
resistance, diabetes, and the metabolic syndrome,” Journal of
Clinical Investigation, vol. 116, no. 7, pp. 1784–1792, 2006.
[41] J. J. D´ ıez and P. Iglesias, “The role of the novel adipocyte-
derived hormone adiponectin in human disease,” European
Journal of Endocrinology, vol. 148, no. 3, pp. 293–300, 2003.
[42] S. J. Robins, “PPARα ligands and clinical trials: cardiovascular
risk reduction with ﬁbrates,” Journal of Cardiovascular Risk,
vol. 8, no. 4, pp. 195–201, 2001.
[43] B. Staels and J.-C. Fruchart, “Therapeutic roles of peroxisome
proliferator-activated receptor agonists,” Diabetes, vol. 54, no.
8, pp. 2460–2470, 2005.
[44] P. R. Shepherd and B. B. Kahn, “Glucose transporters and
insulin action: implications for insulin resistance and diabetes
mellitus,” The New England Journal of Medicine, vol. 341, no.
4, pp. 248–257, 1999.
[45] G. I. Shulman, “Cellular mechanisms of insulin resistance,”
Journal of Clinical Investigation, vol. 106, no. 2, pp. 171–176,
2000.
[46] N. Takahashi, M. Nagamine, S. Tanno, W. Motomura, Y.
Kohgo, and T. Okumura, “A diacylglycerol kinase inhibitor,
R59022, stimulates glucose transport through a MKK3/6-p38
signaling pathway in skeletal muscle cells,” Biochemical and
Biophysical Research Communications, vol. 360, no. 1, pp. 244–
250, 2007.
[47] Y. Yamamoto, Y. Yoshimasa, M. Koh et al., “Constitu-
tively active mitogen-activated protein kinase kinase increases
GLUT1 expression and recruits both GLUT1 and GLUT4 at
the cell surface in 3T3-L1 adipocytes,” Diabetes,v o l .4 9 ,n o .3 ,
pp. 332–339, 2000.
[48] S. H. Kim, E.-J. Shin, E.-D. Kim, T. Bayaraa, S. C. Frost, and
C.-K. Hyun, “Berberine activates GLUT1-mediated glucose
uptake in 3T3-L1 adipocytes,” Biological and Pharmaceutical
Bulletin, vol. 30, no. 11, pp. 2120–2125, 2007.
[49] N. Liu, L. Y. Jia, and Q. S. Sun, “Chemical constituents of Abu-
tilon indicum (L.) Sweet,” Journal of Shenyang Pharmaceutical
University, vol. 26, pp. 196–197, 2009.
[50] J. Chen, J. Liu, L. Zhang et al., “Pentacyclic triterpenes.
Part 3: synthesis and biological evaluation of oleanolic acid
derivatives as novel inhibitors of glycogen phosphorylase,”
Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 11, pp.
2915–2919, 2006.